An assessment of the efficacy and safety of orlistat for the long-term management of obesity

Journal of Nutritional Biochemistry

Volumn 9, Issue 9, 1998, Pages 516-521

  Harp, Joyce B ^a,b  

^a IL   (United States)

^b University of North Carolina   (United States)

Author keywords

Dietary fat; Lipase inhibitor; Obesity; Orlistat; Weight loss

Indexed keywords

BETA CAROTENE; PLACEBO; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; VITAMIN D;

BLOOD PRESSURE; CALORIC INTAKE; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FLATULENCE; HUMAN; LIPID ABSORPTION; OBESITY; VITAMIN BLOOD LEVEL;

EID: 0032167656     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-2863(98)00006-0     Document Type: Conference Paper

References (49)

1. 1 Golay, A. and Bobbioni, E. (1997). The role of dietary fat in obesity. Int. J. Obes. 3, S2-S11
2. 2 Lissner, L. and Heitmann, B.L. (1995). Dietary fat and obesity: Evidence from epidemiology. Eur. J. Clin. Nutr. 49, 79-90
3. 3 West, K. and Kalbfleisch, J. (1971). Influence of nutritional factors on prevalence of diabetes. Diabetes 20, 99-108
4. 4 Sims, E.A.H., Danforth, E. Jr, Horton, E.S., Bray, G.A., Glennon, J.A., and Salans, L.B. (1973). Endocrine and metabolic effects of experimental obesity in man. Rec. Prog. Horm. Res. 23, 457-487
5. 5 Drewnowski, A., Brunzell, J.D., Sande, K., Iverius, P.H., and Greenwood, M.R.C. (1985). Sweet tooth reconsidered: Taste responsiveness in human obesity. Physiol. Behav. 35, 617-622
6. 6 Duncan, K., Bacon, J., and Weinsier, R., (1991). The effect of high and low energy diets on satiety, energy intake, and eating time of obese and non-obese subjects. Am. J. Clin. Nutr. 53, 1124-1129
7. 7 Flatt, J., Ravussin, E., Acheson, K., and Jequier, E. (1985). Effects of dietary fat on postprandial substrate oxidation and on carbohydrate and fat balances. J. Clin. Invest. 76, 1019-1024
8. 8 Foreyt, J. and Goodrick, G. (1992). Potential impact of sugar and fat substitutes in the American diet. J. Natl. Cancer Inst. Monog. 12, 99-103
9. 9 Peters, J.C., Lawson, K.D., Middleton, S.J., and Triebwasser, K.C. (1997). Assessment of the nutritional effect of olestra, a nonabsorbed fat replacement: Summary. J. Nutr. 127, 1719S-1728S
10. 10 Heini, A.F. and Weinsier, R.L. (1997). Divergent trends in obesity and fat intake patterns: The American paradox. Am. J. Med. 102, 259-264
11. 11 National Research Council. (1989). Diet and Health, Washington, DC, National Academy Press
12. 12 Block, G., Rosenberger, W.F., and Patterson, B.H. (1988). Calories fat and cholesterol: intake patterns in the US population by race, sex, and age. Am. J. Public Health 78, 1150-1155
13. 13 Shiau, Y.K. (1987). Lipid digestion and absorption. In Physiology of the Gastrointestinal Tract (L.R. Johnson ed.), pp. 1527-1556, Raven Press, New York
14. 14 Ghishan, F.K., Moran, J.R., Durie, P.R., and Greene, H.L. (1984). Isolated congenital lipase-colipase deficiency. Gastroenterology 86, 1580-1582
15. 15 Wang, C.S. and Hartshuck, J.A. (1993). Bile salt-activated lipase. A multiple function lipolytic enzyme. Biochem. Biophys. Acta. 1166, 1-19
16. 16 Abrahms, C., Hamosh, M., Dutta, S.K., Hubbard, V.S., and Hamosh, P. (1987). Role of nonpancreatic lipolytic activity in exocrine pancreatic insufficiency. Gastroenterology 92, 125-129
17. 17 Weibel, E.K., Hadvary, P., Hochuli, E., Kupfer, E., and Lengsfeld, H. (1987). Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I producing organism, fermentation, isolation, biological activity. J. Antibiot. 40, 1081-1085
18. 18 Hochuli, E., Kupfer, E., Maurer, R., Meister, W., Mercadel, Y., and Schmidt, K. (1987). Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. II. Chemistry and structure elucidation. J. Antibiot. 40, 1086-1091
19. 19 Hadvary, P., Lengsfeld, H., and Wolfer, H. (1988). Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem. J. 256, 357-361
20. 20 Zhi, J., Melia, A.T., Funk, C., Viger-Chougnet, A., Hopfgartner, G., Lausecker, B., Wang, K., Fulton, J.S., Gabriel, L., and Mulligan, T.E. (1996). Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J. Clin. Pharm. 36, 1006-1011
21. 21 Weber, C., Tam, Y.K., Schmidtke-Schrezenmeier, G., Jonkmann, J.H., and van Brummelen, P. (1996). Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur. J. Clin. Pharm. 51, 87-90
22. 22 Zhi, J., Melia, A.T., Guerciolini, R., Koss-Twardy, S.G., Passe, S.M., Rakhit, A., and Sadowski, J.A. (1996). The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J. Clin. Pharm. 36, 659-666
23. 23 Melia, A.T., Mulligan, T.E., and Zhi, J. (1996). The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J. Clin. Pharm. 36, 654-658
24. 24 Melia, A.T., Mulligan, T.E., and Zhi, J. (1996). Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J. Clin. Pharm. 36, 352-355
25. 25 Melia, A.T., Zhi, J., Koss-Twardy, S.G., Min, B.H., Smith, B.L., Freundlich, N.L., Arora, S., and Passe, S.M. (1995). The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J. Clin. Pharm. 35, 840-843
26. 26 Zhi, J., Melia, A.T., Koss-Twardy, S.G., Min, B., Guerciolini, R., Freundlich, N.L., Milla, G., and Patel, I.H. (1995). The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J. Clin. Pharm. 35, 521-525
27. 27 Hartmann, D., Guzelhan, C., Zuiderwijk, P.B., and Odink, J. (1996). Lack of interaction between orlistat and oral contraceptives. Eur. J. Clin. Pharm. 50, 421-424
28. 28 Guerciolini, R. (1997). Mode of action of orlistat. Int. J. Obes. 3, S12-S23
29. 29 Hogan, S., Fleury, A., Hadvary, P., Lengsfeld, H., Meier, M.K., Triscari, J., and Sullivan, A.C. (1987). Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase. Int. J. Obes. 11, 35-42
30. 30 Ackroff, K. and Selafani, A. (1996). Effects of the lipase inhibitor orlistat on intake and preference for dietary fat in rats. Am. J. Physiol. 271, R48-54
31. 31 Zhi, J., Melia, A.T., Guerciolini, R., Chung, J., Kinberg, J., Hauptman, J.B., and Patel, I.H. (1994). Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin. Pharm. Ther. 56, 82-85
32. 32 Hauptman, J.B., Jeunet, F.S., and Hartmann, D. (1992). Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin) Am. J. Clin. Nutr. 55, 309S-313S
33. 33 Hartmann, D., Hussain, Y., Guzelhan, C., and Odink, J. (1993). Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake. Br. J. Clin. Pharm. 36, 266-270
34. 34 Guzelhan, C., Odink, J., Niestijl Jansen-Zuidema, J.J., and Hartmann, D. (1994). Influence of dietary composition on the inhibition of fat absorption by orlistat. J. Inter. Med. Res. 22, 255-265
35. 35 Drent, M.L. and van der Veen, E.A. (1995). First clinical studies with orlistat: A short review. Obesity Res. 3, 623S-625S
36. 36 Drent, M.L., Larsson, I., William-Olsson, T., Quaade, F., Czubayko, F., von Bergmann, K., Strobel, W., Sjostrom, L., and van der Veen EA. (1995). orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study. Int. J. Obes. 19, 221-226
37. 37 James, W.P.T., Avenell, A., and Whitehead, J. (1997). A one-year trial to assess the value of orlistat in the management of obesity. Int. J. Obes. 21, S24-S30
38. 38 Goldstein, D.J. (1992). Beneficial health effects of modest weight loss. Int. J. Obes. 16, 397-415
39. 39 Rossner, S. (1997). Unpublished data on the internet, from the Eighth European Congress on Obesity
40. 40 Hoffman, A.F. (1976). Fat digestion: the interaction of lipid digestion products with micellar bile acid solutions. In Lipid Absorption: Biochemical and Clinical Aspects. (K. Rommelk, H. Goebell, and R. Bohmer, (eds.), pp 3-21, University Park Press, Baltimore
41. 41 Tonstad, S., Pometta, D., Erkelens, D.W., Ose, L., Moccetti, T., Schouten, J.A., Golay, A., Reitsma, J., Del Bufalo, A., and Pasotti, E. et al. (1994). The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur. J. Clin. Pharm. 46, 405-410
42. 42 Hopman, W.P.M., Jansen, J.B.M.J., Rosenbusch, G., and Lamars, C.B.H.W. (1984). Effect of equimolar amounts of long-chain triglycerides and medium-chain triglycerides on plasma cholecystokinin and gallbladder contraction. Am. J. Clin. Nutr. 39, 356-359
43. 43 Froehlich, F., Hartmann, D., Guezelhan, C., Gonvers, J.J., Jansen, J.B., and Fried, M. (1996). Influence of orlistat on the regulation of gallbladder contraction in man: A randomized double-blind placebo-controlled crossover study. Dig. Dis. Sci. 41, 2404-2408
44. 44 Melia, A.T., Koss-Twardy, S.G., and Zhi, J. (1996). The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J. Clin. Pharm. 36, 647-653
45. 45 Zhi, J., Melia, A.T., Koss-Twardy, S.G., Arora, S., and Patel, I.H. (1996). The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J. Clin. Pharm. 36, 152-159
46. 46 Spaulding, S.W., Chopra, I.J., Sherwin, R.S., and Lyall, S.S. (1976). Effect of caloric restriction and dietary composition on serum T3 levels and reverse T3 in man. J. Clin. Endo. Metab. 42, 197-200
47. 47 Young, J.B. and Lansberg, L. (1977). Suppression of sympathetic nervous system during fasting. Science 196, 1473-1475
48. 48 Goldstein, S., Harp, J.B., and Phillips, L.S. (1991). Nutrition and somatomedin XXII: Molecular regulation of insulin-like growth factor-1 during fasting and refeeding in rats. J. Molec. Endo. 6, 33-43
49. 49 Drent, M.L., Popp-Snijders, C., Ader, H.J., Jansen, J.B., and van der Veen, E.A. (1995). Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects. Obesity Res. 3, 573-581